Cody Cichowitz1, Patrick C Carroll1, John J Strouse1, Carlton Haywood1, Sophie Lanzkron1. 1. From the Departments of Psychiatry and Behavioral Medicine, Pediatrics, and Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, and the Division of Hematology, Duke University School of Medicine, Durham, North Carolina.
Abstract
OBJECTIVES: Neurocognitive dysfunction is an important complication of sickle cell disease (SCD), but little is published on the utility of screening tests for cognitive impairment in people with the disease. The purpose of this study was to evaluate the Montreal Cognitive Assessment (MoCA) as a screening tool and identify predictors of MoCA performance in adults with sickle cell disease. METHODS: We conducted a retrospective, cross-sectional study of the first 100 adult patients with SCD who completed the MoCA as part of routine clinical care at the Johns Hopkins Sickle Cell Center for Adults. We abstracted demographic, laboratory, and clinical data from each participant's electronic medical record up to the date that the MoCA was administered. The factorial validity of each MoCA domain was analyzed using standard psychometric statistics. We evaluated the abstracted data for associations with the composite MoCA score and looked for independent predictors of performance using multivariable regressions. RESULTS: Components of the MoCA performed well in psychometric analyses and identified deficits in executive function that were described in other studies. Forty-six percent of participants fell below the cutoff for mild cognitive impairment. Increased education was an independent predictor of increased MoCA score (3.1, 95% confidence interval [CI] 1.5-4.7), whereas cerebrovascular accidents and chronic kidney disease were independent predictors of decreased score (-3.3, 95% CI -5.7 to -0.97 and -3.2, 95% CI -6.2 to -0.11, respectively). When analysis was restricted to patients with SCA, increased education (3.7, 95% CI 2.2-5.2) and a history of hydroxyurea therapy (2.0, 95% CI -0.022 to 4.0) were independent predictors of a higher score, whereas chronic kidney disease (-3.3, 95% CI -6.4 to -0.24) and increased aspartate transaminase (-0.045, 95% CI -0.089 to -0.0010) were independent predictors of a decreased score. CONCLUSIONS: The MoCA showed promise by identifying important cognitive deficits and associations with chronic complications and therapy.
OBJECTIVES:Neurocognitive dysfunction is an important complication of sickle cell disease (SCD), but little is published on the utility of screening tests for cognitive impairment in people with the disease. The purpose of this study was to evaluate the Montreal Cognitive Assessment (MoCA) as a screening tool and identify predictors of MoCA performance in adults with sickle cell disease. METHODS: We conducted a retrospective, cross-sectional study of the first 100 adult patients with SCD who completed the MoCA as part of routine clinical care at the Johns Hopkins Sickle Cell Center for Adults. We abstracted demographic, laboratory, and clinical data from each participant's electronic medical record up to the date that the MoCA was administered. The factorial validity of each MoCA domain was analyzed using standard psychometric statistics. We evaluated the abstracted data for associations with the composite MoCA score and looked for independent predictors of performance using multivariable regressions. RESULTS: Components of the MoCA performed well in psychometric analyses and identified deficits in executive function that were described in other studies. Forty-six percent of participants fell below the cutoff for mild cognitive impairment. Increased education was an independent predictor of increased MoCA score (3.1, 95% confidence interval [CI] 1.5-4.7), whereas cerebrovascular accidents and chronic kidney disease were independent predictors of decreased score (-3.3, 95% CI -5.7 to -0.97 and -3.2, 95% CI -6.2 to -0.11, respectively). When analysis was restricted to patients with SCA, increased education (3.7, 95% CI 2.2-5.2) and a history of hydroxyurea therapy (2.0, 95% CI -0.022 to 4.0) were independent predictors of a higher score, whereas chronic kidney disease (-3.3, 95% CI -6.4 to -0.24) and increased aspartate transaminase (-0.045, 95% CI -0.089 to -0.0010) were independent predictors of a decreased score. CONCLUSIONS: The MoCA showed promise by identifying important cognitive deficits and associations with chronic complications and therapy.
Authors: F Bernaudin; S Verlhac; F Fréard; F Roudot-Thoraval; M Benkerrou; I Thuret; R Mardini; J P Vannier; E Ploix; M Romero; C Cassé-Perrot; M Helly; E Gillard; G Sebag; H Kchouk; J P Pracros; B Finck; J N Dacher; V Ickowicz; C Raybaud; M Poncet; E Lesprit; P H Reinert; P Brugières Journal: J Child Neurol Date: 2000-05 Impact factor: 1.987
Authors: Ziad S Nasreddine; Natalie A Phillips; Valérie Bédirian; Simon Charbonneau; Victor Whitehead; Isabelle Collin; Jeffrey L Cummings; Howard Chertkow Journal: J Am Geriatr Soc Date: 2005-04 Impact factor: 5.562
Authors: Vikki G Nolan; Adeboye Adewoye; Clinton Baldwin; Ling Wang; Qianli Ma; Diego F Wyszynski; John J Farrell; Paola Sebastiani; Lindsay A Farrer; Martin H Steinberg Journal: Br J Haematol Date: 2006-06 Impact factor: 6.998
Authors: K Ohene-Frempong; S J Weiner; L A Sleeper; S T Miller; S Embury; J W Moohr; D L Wethers; C H Pegelow; F M Gill Journal: Blood Date: 1998-01-01 Impact factor: 22.113
Authors: Elliott P Vichinsky; Lynne D Neumayr; Jeffrey I Gold; Michael W Weiner; Randall R Rule; Diana Truran; Jeffrey Kasten; Barry Eggleston; Karen Kesler; Lillian McMahon; Eugene P Orringer; Thomas Harrington; Karen Kalinyak; Laura M De Castro; Abdullah Kutlar; Cynthia J Rutherford; Cage Johnson; Joel David Bessman; Lanetta B Jordan; F Daniel Armstrong Journal: JAMA Date: 2010-05-12 Impact factor: 56.272
Authors: Michael R DeBaun; Sharada A Sarnaik; Mark J Rodeghier; Caterina P Minniti; Thomas H Howard; Rathi V Iyer; Baba Inusa; Paul T Telfer; Melanie Kirby-Allen; Charles T Quinn; Françoise Bernaudin; Gladstone Airewele; Gerald M Woods; Julie Ann Panepinto; Beng Fuh; Janet K Kwiatkowski; Allison A King; Melissa M Rhodes; Alexis A Thompson; Mark E Heiny; Rupa C Redding-Lallinger; Fenella J Kirkham; Hernan Sabio; Corina E Gonzalez; Suzanne L Saccente; Karen A Kalinyak; John J Strouse; Jason M Fixler; Mae O Gordon; J Phillip Miller; Michael J Noetzel; Rebecca N Ichord; James F Casella Journal: Blood Date: 2011-11-17 Impact factor: 22.113
Authors: R Scott Mackin; Philip Insel; Diana Truran; Elliot P Vichinsky; Lynne D Neumayr; F D Armstrong; Jeffrey I Gold; Karen Kesler; Joseph Brewer; Michael W Weiner Journal: Neurology Date: 2014-02-12 Impact factor: 9.910
Authors: K E Watkins; D K Hewes; A Connelly; B E Kendall; D P Kingsley; J E Evans; D G Gadian; F Vargha-Khadem; F J Kirkham Journal: Dev Med Child Neurol Date: 1998-08 Impact factor: 5.449
Authors: James G Taylor; Vikki G Nolan; Laurel Mendelsohn; Gregory J Kato; Mark T Gladwin; Martin H Steinberg Journal: PLoS One Date: 2008-05-07 Impact factor: 3.240